Business
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer, will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference. The conference is being held April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Ontario. ...
About this update from Promis Neurosciences Inc.
[{"type":"text","content":"Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer, will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference.","length":393,"tagName":"p"},{"type":"text","content":"The conference is being held April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Ontario. ProMIS will present on Tuesday, April 21 at 2:30-3:00pm ET and will be available for one-on-one meetings with investors throughout the conference. A webcast of the company presentation will be available to registered attendees via the conference portal.","length":361,"tagName":"p"},{"type":"text","content":"We look forward to sharing our recent progress related to our PRECISE-AD Phase 1b clinical trial and welcoming discussions with investors and industry partners regarding our differentiated approach to targeting toxic misfolded proteins in Alzheimer's and other neurodegenerative diseases. We are on track to complete a six-month interim analysis of blinded safety and biomarker data in mid-2026. Full patient dosing is expected to be completed by year-end 2026, with presentation of unblinded top-line data anticipated in early 2027.","length":537,"tagName":"p"},{"type":"text","content":"About ProMIS Neurosciences Inc.","length":31,"tagName":"p"},{"type":"text","content":"ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company's proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson's disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).","length":798,"tagName":"p...